CN103690525A - Application of Artoxanthochromane in preparation of medicine for treating tongue cancer - Google Patents
Application of Artoxanthochromane in preparation of medicine for treating tongue cancer Download PDFInfo
- Publication number
- CN103690525A CN103690525A CN201310636289.1A CN201310636289A CN103690525A CN 103690525 A CN103690525 A CN 103690525A CN 201310636289 A CN201310636289 A CN 201310636289A CN 103690525 A CN103690525 A CN 103690525A
- Authority
- CN
- China
- Prior art keywords
- artoxanthochromane
- tongue cancer
- medicine
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of Artoxanthochromane in preparation of a medicine for treating tongue cancer and belongs to the technical field of novel application of medicines. In vitro MTT ((3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) anti-tumor activity evaluation discovers that Artoxanthochromane has a remarkable inhibition effect on the growth of human tongue cancer cell line PTca8113 and T6. Therefore, Artoxanthochromane can be used for preparing a tongue cancer resistance medicine and has an excellent developing application prospect. The application of Artoxanthochromane in preparation of the medicine for treating tongue cancer is disclosed for the first time, and Artoxanthochromane has a strong inhibition activity to tongue cancer cells, and remarkable progress is obtaine.
Description
Technical field
The present invention relates to the new purposes of compd A rtoxanthochromane, relate in particular to the application of Artoxanthochromane in preparation treatment carcinoma of tongue medicine.
Background technology
Cancer is to one of disease of human life's health hazard maximum, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be natural product or derivatives thereof, if paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, find anticancer compound or lead compound has great importance.
The compd A rtoxanthochromane the present invention relates to is one and within 2013, delivers (Horng-Huey Ko, et al., A Novel MonoterpeneStilbene Adduct with a4, 4-Dimethyl-2, 3-diphenylchromane Skeleton from Artocarpus xanthocarpus.chemistry & biodiversity, 2013 (10): noval chemical compound 1269-1275.), this compound has brand-new framework types, this compound can be removed oxygen-derived free radicals (Horng-Huey Ko, et al., A Novel MonoterpeneStilbene Adduct with a4, 4-Dimethyl-2, 3-diphenylchromane Skeleton from Artocarpus xanthocarpus.chemistry & biodiversity, 2013 (10): 1269-1275.), the purposes of the Artoxanthochromane the present invention relates in preparation treatment carcinoma of tongue medicine belongs to open first.
Summary of the invention
The object of the invention is to, according to not finding that it has the present situation of the report of anti-carcinoma of tongue activity in existing Artoxanthochromane research, provides the application of Artoxanthochromane in the anti-carcinoma of tongue medicine of preparation.
Described compd A rtoxanthochromane structure is as shown in formula I:
The present invention finds by the evaluation of external MTT anti-tumor activity, Artoxanthochromane also has significant inhibitory action to the growth of people's Human Tongue Carcinoma Lines strain PTca8113 and T6, and the IC50 value that suppresses this 2 strain Growth of Cells is respectively 1.97 ± 0.52 μ M and 1.75 ± 0.57 μ M.Therefore, Artoxanthochromane can, for the preparation of anti-carcinoma of tongue medicine, have good development prospect.
Purposes for the Artoxanthochromane the present invention relates in preparation treatment carcinoma of tongue medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for Human Tongue Carcinoma Lines is active strong, possess outstanding substantive distinguishing features, the control for carcinoma of tongue simultaneously obviously has significant progress.
The specific embodiment
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The preparation method of compd A rtoxanthochromane involved in the present invention is referring to document (Horng-Huey Ko, et al., A Novel MonoterpeneStilbene Adduct with a4,4-Dimethyl-2,3-diphenylchromane Skeleton from Artocarpus xanthocarpus.chemistry & biodiversity, 2013 (10): 1269-1275.), prepare according to the method described above compd A rtoxanthochromane.
Embodiment 1: the preparation of compd A rtoxanthochromane tablet involved in the present invention:
Get 5 and digest compound Artoxanthochromane, add 195 grams, dextrin, mix, conventional tabletting is made 1000.
Embodiment 2: the preparation of compd A rtoxanthochromane capsule involved in the present invention:
Get 5 and digest compound Artoxanthochromane, add 195 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example 1: adopt the growth inhibited effect of mtt assay assessing compound Artoxanthochromane to the strain of people's Human Tongue Carcinoma Lines
1. method: the cell in growth logarithmic (log) phase: people's Human Tongue Carcinoma Lines strain PTca8113 and T6(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4concentration kind is in 96 orifice plates.After cell culture 24h is adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Artoxanthochromane of 0.01 μ M and 0.001 μ M.Cultivate after 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4h, then along culture fluid top, suck 100 μ L supernatants, add 100 μ L DMSO, 10min is placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD drug treating/Δ OD blank * 100.
2. result: Artoxanthochromane has significant inhibitory action to the growth of people's Human Tongue Carcinoma Lines strain P PTca8113 and T6.The IC50 value that this compound suppresses people Human Tongue Carcinoma Lines strain PTca8113 and T6 growth is respectively 1.97 ± 0.52 μ M and 1.75 ± 0.57 μ M.
By above-described embodiment, shown, Artoxanthochromane of the present invention has good inhibitory action to the growth of people's Human Tongue Carcinoma Lines strain PTca8113 and T6.Prove thus, it is active that Artoxanthochromane of the present invention has anti-carcinoma of tongue, can be for the preparation of anti-carcinoma of tongue medicine.
Claims (1)
- The application of 1.Artoxanthochromane in treatment carcinoma of tongue medicine, described compd A rtoxanthochromane structure is as shown in formula I:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310636289.1A CN103690525A (en) | 2013-12-02 | 2013-12-02 | Application of Artoxanthochromane in preparation of medicine for treating tongue cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310636289.1A CN103690525A (en) | 2013-12-02 | 2013-12-02 | Application of Artoxanthochromane in preparation of medicine for treating tongue cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103690525A true CN103690525A (en) | 2014-04-02 |
Family
ID=50352299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310636289.1A Pending CN103690525A (en) | 2013-12-02 | 2013-12-02 | Application of Artoxanthochromane in preparation of medicine for treating tongue cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103690525A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9701655B2 (en) | 2014-02-07 | 2017-07-11 | Novogen Limited | Functionalised benzopyran compounds and use thereof |
-
2013
- 2013-12-02 CN CN201310636289.1A patent/CN103690525A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| HORNG-HUEY KO，ET AL.: "A Novel Monoterpene-Stilbene Adduct with a 4,4-Dimethyl-2,3-diphenylchromane Skeleton from Artocarpus xanthocarpus", 《CHEMISTRY & BIODIVERSITY》 * |
| 姚金光 等: "舌鳞癌患者治疗前后血中LPO、SOD 水平的变化及意义", 《广西医学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9701655B2 (en) | 2014-02-07 | 2017-07-11 | Novogen Limited | Functionalised benzopyran compounds and use thereof |
| US10370349B2 (en) | 2014-02-07 | 2019-08-06 | Kazia Therapeutics Limited | Functionalised benzopyran compounds and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105250250A (en) | Application of Nootkatone in preparation of medicine for treating nasopharyngeal carcinoma | |
| CN103690525A (en) | Application of Artoxanthochromane in preparation of medicine for treating tongue cancer | |
| CN103251609A (en) | Application of Aspeverin in preparation of medicines for treating tongue cancer | |
| CN103638008B (en) | The application of Artoxanthochromane in treatment skin carcinoma medicine | |
| CN103585145A (en) | Application of Artoxanthochromane in preparation of prostate cancer treatment drugs | |
| CN103705503A (en) | Applications of Artoxanthochromane in medicines treating breast cancer | |
| CN105267193A (en) | Application of Periconianone B to preparation of medicine for treating ovarian cancer | |
| CN105456243A (en) | Application of Flabelliferin B in preparing medicine for treating nasopharynx cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN103463042B (en) | Application of Lycojaponicumin A in drugs for treating prostatic cancer | |
| CN103462959B (en) | Incarviatone A is preparing the application in Hepatoma therapy medicine | |
| CN103463053B (en) | Lycojaponicumin A is preparing the application in Hepatoma therapy medicine | |
| CN102872138B (en) | Application of Houttuynoid C in drug for treating colorectal cancer | |
| CN103446150B (en) | Lycojaponicumin C is preparing the application in Hepatoma therapy medicine | |
| CN103536598A (en) | Application of compound in preparation of drug for treating liver cancer | |
| CN102872141B (en) | Application of Houttuynoid E in drug for treating liver cancer | |
| CN103655552A (en) | Application of Manzamenone O in pancreas cancer treatment medicines | |
| CN103585144A (en) | Application of Artoxanthochromane in medicines for treating bladder cancer | |
| CN103520175B (en) | The application of a kind of compound in preparation treatment cervical cancer medicine | |
| CN102861052B (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN103446086B (en) | The application of Incarviatone A in preparation treatment gastric cancer medicament | |
| CN103446089B (en) | The application of Incarviatone A in preparation treatment medicine for nasopharyngeal | |
| CN105326820A (en) | Application of Nardoaristolone B in preparation of liver cancer treatment drug | |
| CN105395536A (en) | Application of Flabelliferin A in preparation of drugs treating ileocecal cancer | |
| CN105287492A (en) | Application of Mollanol A in preparation of medicines for treating cervical carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140402 |